Connect your AI

Crinetics Pharmaceuticals CRNX Shares (Basic)

Shares (Basic) at other companies

Neurocrine BiosciencesNBIX

100.5M+0.8%

Corcept TherapeuticsCORT

104.4M+0.3%

Viking TherapeuticsVKTX

115.6M+3.1%

Catalyst PharmaceuticalCPRX

122.3M+0.6%

Ultragenyx PharmaceuticalRARE

100.6M+4.5%

Mineralys Therapeutics, Inc.MLYS

82.8M+55.8%

Other financials

Income statement

Revenue$10.7M+2,873%

Gross profit$10.5M+2,818%

Operating income-$140.4M-26.0%

Net income-$127.8M-32.1%

EPS (diluted)-$1.23-18.3%

Balance sheet

Cash & equivalents$115.1M+20.1%

Total debt$47.9M-5.8%

Total equity$1.3B+2.1%

Total assets$1.4B+2.9%

Cash flow

Operating cash flow-$124.7M-41.0%

CapEx$820.0K-33.8%

Free cash flow-$125.5M-40.0%

Valuation

Market cap$3.79B+21.9%

Profitability

Gross margin150%-15.6pp

Operating margin-3,020.3%-1,463pp

Net margin-2,747.2%-1,328pp

FCF margin-2,321.7%-1,122pp

Returns & leverage

Return on equity-39.2%+14.5pp

Debt / equity0×0.0×

Current ratio18.6×-3.9×

Where this comes from

Reported directly by Crinetics Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfSharesOutstandingBasic.

The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Crinetics Pharmaceuticals's shares (basic).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Crinetics Pharmaceuticals's shares (basic)?: Crinetics Pharmaceuticals (CRNX) reported shares (basic) of 104.1M in Q1 2026.
How has Crinetics Pharmaceuticals's shares (basic) changed year-over-year?: Crinetics Pharmaceuticals's shares (basic) increased by 11.8% year-over-year, from 93.1M to 104.1M.
What is the long-term trend for Crinetics Pharmaceuticals's shares (basic)?: Over 3 years (2022 to 2025), Crinetics Pharmaceuticals's shares (basic) has grown at a 22.1% compound annual growth rate (CAGR), from 206M to 375.2M.
What does shares (basic) mean?: The time-weighted average number of common shares outstanding during the period, used as the denominator for basic EPS calculations.